Hemp’s Synthetic Ban Starts Today, Plus Avicanna’s EBITDA Turnaround
In today’s Trade To Black podcast presented by Flowhub, Shadd Dales and Anthony Varrell welcome Avicanna (TSX: AVCN) CEO Aras Azadian to discuss Q3 2026, as the first phase of the federal hemp ban takes effect for synthetic cannabinoids the plant can’t produce naturally. FundCanna CEO Adam Stettner then joins to weigh in on state reform and the DEA’s latest registration decisions.
Off the top, Glass House Brands shares fell about 34% to $1.23 after the company swapped auditors twice in two months. Its Q3 results are due Monday.
Avicanna, which marks its 10th anniversary next week, returned to positive adjusted EBITDA of $0.22 million, a $1.01 million improvement from a year-ago loss. Revenue was $5.73 million, up 2% from last quarter despite reimbursement changes at Veterans Affairs Canada. Operating expenses fell 30% to $3.19 million, and gross margin was 51%. Azadian says the reimbursement changes cost peers 20% to 25% of their revenue, while Avicanna held its losses to 12% to 13% by cutting costs and automating. Its proprietary products now make up 31% of sales on its MyMedi platform.
Azadian says early demand for the QUIX rapid-onset portfolio has exceeded expectations. The technology works across CBD, CBG, CBN and THC, as well as gummies, beverages and capsules. He also describes new support from Canada’s federal government, including help from trade commissioners and export financing. In the U.S., he sees opportunities to license Avicanna’s intellectual property and clinical model, either to a pharmaceutical company or to a multi-state operator with a medical focus.
Stettner points to Wisconsin, where incoming Democratic Gov. David Crowley says legalization could raise $80 million to $170 million a year and help offset Medicaid cuts. The next Assembly speaker calls it a priority. Stettner says states are moving because they can see the tax revenue flowing to their neighbors. Varrell argues that SAFE Banking is the only federal bill with a realistic path.
Marijuana Moment reports that the DEA has pushed back on medical marijuana businesses seeking rescheduling protections in at least six states and Washington, D.C., after approving more than 900 applicants. Varrell argues the treaty exemption used to reschedule medical marijuana limits what the agency can approve. Stettner adds that registrations may have started too early, before broader rescheduling was settled.
Is 2027 the year states lead? Tune in to hear the full conversation about the synthetic ban.

